永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

午间休市 04-14 11:42:41

3.600

+0.010

+0.28%

最高3.620	最低3.450	成交量55.08万
今开3.620	昨收3.590	日振幅4.74%
总市值22.25亿	流通市值22.25亿	总股本6.18亿
成交额194.94万	换手率0.09%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.6,"timestamp":1776138161865,"preClose":3.59,"halted":0,"volume":550805,"delay":0,"changeRate":0.0027855153203343265,"floatShares":618000000,"shares":618000000,"eps":-0.4828073967903381,"marketStatus":"午间休市","change":0.01,"latestTime":"04-14 11:42:41","open":3.62,"high":3.62,"low":3.45,"amount":1949363,"amplitude":0.047354,"askPrice":3.66,"askSize":1000,"bidPrice":3.51,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.4759101482647618,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776142800000},"marketStatusCode":3,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.59,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":0.987198,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/wiki","defaultTab":"wiki","newsList":[{"id":"2627983499","title":"港股异动 | 绿叶制药(02186)午前涨近3% 近日自研创新药LY03020中国Ⅱ期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627983499","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627983499?lang=zh_cn&edition=full","pubTime":"2026-04-14 11:54","pubTimestamp":1776138882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药午前涨近3%，截至发稿，涨2.52%，报2.85港元，成交额5323.6万港元。消息面上，近日，绿叶制药发布公告，本集团自主研发的创新药LY03020的中国Ⅱ期临床已完成首例患者入组。此前，LY03020亦已在美国获准开展临床试验，是本集团在中国和海外同步开发的又一款中枢神经系统治疗领域的创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4585","06978","BK1191","BK1161","02186","BK4588","VXUS","BK1574","159992","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245839","title":"创新药赛道低位整理，港股通创新药ETF易方达（159316）今日净申购达3400万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627245839?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:05","pubTimestamp":1776081908,"startTime":"0","endTime":"0","summary":"4月13日，创新药赛道低位整理，指数层面，恒生港股通创新药指数下跌1.2%，中证创新药产业指数下跌0.6%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)全天获3400万份净申购。中国银河证券指出，当前创新药板块的调整更多是受技术性回调与情绪因素所致，估值底部已基本明确。2026年，创新药板块或呈现明显的结构性分化，具备核心管线临床数据兑现能力和大额商务拓展交易支撑的龙头企业将更具确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041300029668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","BK1161","06978","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627338194","title":"申万宏源：26年一季报披露期临近 关注创新药、CXO及上游","url":"https://stock-news.laohu8.com/highlight/detail?id=2627338194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627338194?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:10","pubTimestamp":1776067851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，截止至4月12日共有8家医药上市公司发布2026Q1业绩预告，其中6家利润同比增长，2家同比下滑。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期，重点推荐。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期其中，CXO板块的业绩增长主要得益于全球创新药行业景气度持续向好，行业新签订单呈现良好增长，国内外医药投融资景气度持续上行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0276","06806","BK1574","CXO","000166","BK0188","BK1147","BK1564","BK1161","159992","BK0183","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627460483","title":"创新药概念震荡回升 君实生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627460483","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627460483?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:47","pubTimestamp":1776048478,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，创新药概念盘中震荡回升，君实生物涨超10%，通化金马一度逼近涨停，常山药业、圣诺生物、荣昌生物、新诺威、三生国健涨幅靠前。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702633963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702633963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688180","BK1515","BK1583","BK0239","06978","BK1161","01877","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710069","title":"7.45亿美元！创新药龙头再获天价大单！","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627710069?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:19","pubTimestamp":1776043140,"startTime":"0","endTime":"0","summary":"4月12日，海思科宣布与美国公司AbbVie Group Holdings Ltd．签订Nav1.8抑制剂授权协议，将获得3000万美元首付款及最高7.15亿美元的里程碑付款，AbbVie还将支持相关开发费用。公司旗下选择性Nav1.8阻断剂HSK55718和HSK51155通过抑制痛觉神经异常放电，意在开发为疼痛治疗药物。　　生物医药领域的创新药对外授权交易持续活跃，近期海思科与艾伯维就Nav1.8抑制剂达成的授权协议进一步印证了这一趋势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-13/doc-inhuihze5709901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627104498","title":"创新药龙头再获天价大单，一季度净利约去年全年2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2627104498","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627104498?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:47","pubTimestamp":1776037620,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　4月12日晚间，海思科连发三份重磅公告，交出了一份极具“反转色彩”的成绩单。　　据海思科2026年第一季度业绩预告，公司预计当期归属于上市公司股东的净利润为4.77亿元至5.57亿元，同比增长923.34%至1094.97%；扣除非经常性损益后的净利润为4.49亿元至5.29亿元，同比增长791.94%至950.86%。21快讯记者注意到，海思科仅一季度净利润，就已接近2025年全年2.60亿元净利润的约两倍。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626617252","title":"瞄准创新药板块！基金经理，新打法曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2626617252","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626617252?lang=zh_cn&edition=full","pubTime":"2026-04-12 17:43","pubTimestamp":1775986980,"startTime":"0","endTime":"0","summary":"伴随各类事件催化进入密集兑现周期，不少基金经理开始切换布局创新药对冲组合风险。　　为对冲持仓波动、稳住组合收益，在老龄化趋势中迎来景气度利好，兼具刚需弹性与防御属性的创新药赛道，正靠着密集的事件驱动逻辑，逐渐成为基金经理调仓避险的重要选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-12/doc-inhufuye5534581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626171216","title":"海思科最新公告：一季度净利同比预增923%-1095%创新药销售保持良好增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626171216","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626171216?lang=zh_cn&edition=full","pubTime":"2026-04-12 15:40","pubTimestamp":1775979644,"startTime":"0","endTime":"0","summary":"海思科公告称，预计2026年第一季度归属于上市公司股东的净利润为4.77亿元-5.57亿元，比上年同期增长923.34%-1094.97%。公司积极拓展市场，创新药销售持续保持良好增长。因此，在研发费用保持较高增长的情况下，公司归属于上市公司股东的净利润及扣除非经常性损益后的净利润仍实现了较高的增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200002766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","BK0077","002653","BK1574","06978","159992","BK0033","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626147650","title":"和讯信息冯禄顺：创新药接下来怎么走","url":"https://stock-news.laohu8.com/highlight/detail?id=2626147650","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626147650?lang=zh_cn&edition=full","pubTime":"2026-04-11 13:28","pubTimestamp":1775885283,"startTime":"0","endTime":"0","summary":"4月10日，咱们解读一下来创新药指数。创新药方向迎来缩量反弹，反弹的核心原因的是，当日高位科技板块开始调整，低位的创新药板块随之迎来修复行情。再看港股创新药，今日港股正常开盘，其走势与A股创新药有所呼应。港股创新药的操作逻辑与A股类似：回踩5周线、5天线时可低吸进场，反弹后及时止盈；一旦跌破5天线，大概率会回踩5周线，毕竟当前股价与5周线存在一定距离。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260411/32138321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06978","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118371","title":"康芝药业：公司目前暂无正在开发中的创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626118371?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:52","pubTimestamp":1775825541,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价从高点回落近50%，公司是否有正在开发中的创新药？康芝药业回复：您好！公司目前暂无正在开发中的创新药。公司在研项目主要聚焦于儿童用药领域，涵盖改良型新药、首仿药以及中药二次开发等方向。敬请广大投资者谨慎决策，注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000039000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","300086","BK0048","06978","BK0070","BK0239","159992","BK1574","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626194044","title":"创新药赛道小幅反弹，港股通创新药ETF易方达（159316）今日净申购达1700万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2626194044","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626194044?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:24","pubTimestamp":1775820298,"startTime":"0","endTime":"0","summary":"4月10日，创新药赛道小幅反弹，指数层面，恒生港股通创新药指数、中证创新药产业指数均上涨0.5%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)全天获1700万份净申购。招银国际指出，生物医药产业定位跃升为新兴支柱产业，预示全链条政策红利将持续释放，AI制药技术突破与中国创新药出海BD爆发形成双重共振，行业基本面有望加速向好。当前国产创新药出海合作已从单一管线授权升级至平台层面合作，跨国药企对中国医药研发实力的认可度正系统性提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041000035247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","159316","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191713","title":"东北制药的“双降”困局：仿制药承压，创新药“烧钱”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191713","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626191713?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:52","pubTimestamp":1775818320,"startTime":"0","endTime":"0","summary":"在集采常态化与医保控费持续深化的背景下，老牌药企东北制药交出了一份并不乐观的2025年成绩单。年报数据显示，公司全年实现营业收入70.75亿元，同比下降5.70%；归母净利润为2.60亿元，同比大幅下滑36.54%。利润降幅远超营收，反映出公司在核心业务上面临的结构性压力。　　东北制药的业务高度依赖传统化学仿制药。在“仿制药难以为继、创新药尚未成型”的夹缝中，东北制药能否熬过这段“青黄不接”的时期，市场将拭目以待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-10/doc-inhtzhty0252049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000597","BK1574","BK0239","159992","BK0191","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626196542","title":"热景生物最新公告：子公司创新药SGT003注射液获临床试验受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2626196542","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626196542?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:49","pubTimestamp":1775814558,"startTime":"0","endTime":"0","summary":"热景生物(688068.SH)公告称，公司控股子公司北京舜景生物医药技术有限公司自主研发的创新药SGT003注射液收到国家药品监督管理局下发的《受理通知书》。SGT003注射液是一款基于NexTreg技术平台开发的新型双特异性抗体候选药物，旨在精准清除肿瘤微环境调节性T细胞，激活抗肿瘤免疫，有望降低传统抗CTLA-4抗体的毒副作用，覆盖广泛实体瘤患者群体。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000031073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","688068","159992","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626607981","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626607981","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626607981?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:24","pubTimestamp":1775809452,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的106要进行b的临床，但是董秘却在互动中回复说和监管部门沟通期临床，请问这是不是刻意误导行为？千红制药回复：尊敬的投资者，您好，公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000027292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","002550","06978","159992","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626338621","title":"两大血液瘤王牌爆卖5亿元难救主，亚盛医药又亏了12亿元，能否熬到创新药盈利拐点｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626338621","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626338621?lang=zh_cn&edition=full","pubTime":"2026-04-09 21:44","pubTimestamp":1775742264,"startTime":"0","endTime":"0","summary":"身披国产肿瘤原创新药领军者、细胞凋亡领域深耕者光环的创新药新贵亚盛医（06855.HK），近日披露的2025年年度报告无疑给市场扔下一枚深水炸弹，这份年报呈现了公司“产品销售猛增、整体业绩亏损”的矛盾反差。年报显示，亚盛医药的核心血液瘤产品矩阵表现亮眼，耐立克?（奥雷巴替尼）与利生妥?（利沙托克拉）合计实现销售收入5.06亿元，商业化收入同比大幅增长90%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699953985.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699953985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","AAPG","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902334","title":"新华制药：有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902334","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902334?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:12","pubTimestamp":1775722325,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：新华制药研发用于治疗阿尔茨海默病的创新药OAB-14，之前公告已经进入二期临床实验了，距离上次公示已经一年了，这款药物进展如何了，是不是今年能上市？巨潮资讯网是公司指定信息披露媒体，有关治疗阿尔茨海默病的创新药OAB-14进展情况，请关注巨潮资讯网公司刊载的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900024773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","000756","BK0239","BK0164","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626904465","title":"医美营收翻倍、创新药加速放量，四环医药（0460.HK）的成长拐点已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2626904465","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626904465?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:02","pubTimestamp":1775721725,"startTime":"0","endTime":"0","summary":"医美业务以14.85亿元的营收、99.6%的同比增速，首次占据总营收比重突破50%（达57%），成为公司第一大收入来源","market":"fut","thumbnail":"https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4355067","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","00460","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626090609","title":"超4000亿，中国创新药出海“爆单”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626090609","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626090609?lang=zh_cn&edition=full","pubTime":"2026-04-09 14:31","pubTimestamp":1775716260,"startTime":"0","endTime":"0","summary":"2026年Q1，中国创新药出海热度持续飙升。据国家药监局披露，Q1中国创新药对外授权交易总额已超过600亿美元，接近2025年全年的一半；截至3月27日，年内已有10款创新药获批上市，其中8款为国产，同样创下同期新高。此外，中国创新药与MNC之间的关系正在重写。热门赛道“涛声依旧”2026年Q1，中国创新药对外授权交易继续向头部赛道集中。此外，ADC依旧是中国创新资产出海最稳定的资产之一。截至目前，国内在小核酸领域已完成3笔出海授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-09/doc-inhtwtfe0942273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626908157","title":"创新药赛道早盘下挫，港股通创新药ETF易方达（159316）逆势获近3000万份净申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2626908157","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626908157?lang=zh_cn&edition=full","pubTime":"2026-04-09 13:07","pubTimestamp":1775711253,"startTime":"0","endTime":"0","summary":"4月9日早盘，创新药赛道小幅下挫，指数层面，恒生港股通创新药指数下跌0.7%，中证创新药产业指数下跌1.0%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)逆势获近3000万份净申购。消息面上，2026年美国癌症研究协会(AACR)年会将于4月17日至22日召开，这是全球肿瘤创新药最重要的数据发布窗口之一。今年共有104家中国药企参会，展示超250款创新药物及近400项前沿研究成果，其中92款为ADC药物，覆盖HER2、Trop2等热门靶点，另有66款小分子及核药、细胞治疗等前沿技术成果同步披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026040900018213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","159316","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625940930","title":"绿叶制药(02186)：创新药LY03020中国Ⅱ期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2625940930","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625940930?lang=zh_cn&edition=full","pubTime":"2026-04-08 22:34","pubTimestamp":1775658898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，本集团自主研发的创新药LY03020的中国Ⅱ期临床已完成首例患者入组。此前，LY03020亦已在美国获准开展临床试验，是本集团在中国和海外同步开发的又一款中枢神经系统治疗领域的创新药。LY03020已在早期研究中展现出积极的疗效和安全性信号。中国Ⅰ期临床研究结果表明，LY03020整体安全耐受性良好，所有治疗中出现的不良事件均为轻至中度，无EPS相关不良事件亦无严重不良事件报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03020","BK1161","06978","02186","BK1191","BK1583","BK1606","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.3199},{"period":"1month","weight":0.4078},{"period":"3month","weight":0.2867},{"period":"6month","weight":-0.1553},{"period":"1year","weight":-0.0911},{"period":"ytd","weight":0.2253}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.00907},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}